HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life
science research and clinical diagnostic products, today announced that
it had received an expected notice from the New York Stock Exchange (the
“NYSE”) stating that the Company is not in compliance with the NYSE’s
continued listing requirements under the timely filing criteria
established in Section 802.01E of the NYSE Listed Company Manual due to
the Company’s delay in filing its Annual Report on Form 10-K for the
fiscal year ended December 31, 2018 (the “2018 Form 10-K”).
As previously disclosed, the reason for the delay is the additional time
needed by Bio-Rad to complete its year-end procedures, including its
assessment of the effectiveness of the Company’s internal control over
financial reporting as of December 31, 2018. Bio-Rad intends to file its
2018 Form 10-K as promptly as possible after its independent registered
public accounting firm completes its audit.
In accordance with NYSE rules, Bio-Rad has contacted the NYSE to discuss
the status of the late filing and is issuing this required press
release. The NYSE informed Bio-Rad that under NYSE rules Bio-Rad will
have six months from the Form 10-K due date to file the 2018 Form 10-K
with the SEC. Bio-Rad can regain compliance with the NYSE listing
standards at any time prior to that date by filing its 2018 Form 10-K.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in
developing, manufacturing, and marketing a broad range of innovative
products for the life science research and clinical diagnostic markets.
With a focus on quality and customer service for over 65 years, our
products advance the discovery process and improve healthcare. Our
customers are university and research institutions, hospitals, public
health and commercial laboratories, biotechnology, pharmaceutical, as
well as applied laboratories that include food safety and environmental
quality. Founded in 1952, Bio-Rad is based in Hercules, California, and
has a global network of operations with more than 8,000 employees
worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more
information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, without
limitation, statements we make regarding the anticipated timing of the
filing of the Company’s 2018 Form 10-K. We have based these statements
on the information now known to us. Although we believe that the
assumptions and expectations reflected in these statements are
reasonable, the timing of completion of the audit process and the filing
of the 2018 Form 10-K in order to come into compliance with the NYSE’s
requirements for continued listing is subject to known and unknown risks
and uncertainties and could vary materially from our current
expectations The Company cautions you not to place undue reliance on
forward-looking statements, which reflect an analysis only and speak
only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any
obligation to update these forward-looking statements.
Contacts
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com